AGC
FOLD

Angelo Gordon & Co’s Amicus Therapeutics FOLD Stock Holding History

Angelo Gordon & Co’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.42M Buy
+100,000
New +$982K 0.13% 43

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Angelo Gordon & Co's FOLD Position: Q4 2025 in Review

Angelo Gordon & Co opened a new position in Amicus Therapeutics (FOLD) in Q4 2025: 100,000 shares worth $1.42M. The stake represents 0.13% of the portfolio and ranks #43 among its holdings.

332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Angelo Gordon & Co held 100,000 shares of Amicus Therapeutics worth $1.42M as of Q4 2025.
  • Amicus Therapeutics was a new Angelo Gordon & Co position in Q4 2025.
  • Amicus Therapeutics made up 0.13% of Angelo Gordon & Co's portfolio in Q4 2025, its #43 holding.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Angelo Gordon & Co's 13F filing for Q4 2025, filed 17 Feb 2026.